web analytics
August 27, 2014 / 1 Elul, 5774
At a Glance
InDepth
Sponsored Post
Jerusalem Mayor Nir Barkat (L) visits the JewishPress.com booth at The Event. And the Winners of the JewishPress.com Raffle Are…

Congratulations to all the winners of the JewishPress.com raffle at The Event



The Israeli Dash to the NASDAQ

Shmuel Zysman

Shmuel Zysman
Photo Credit: Ranit Nachum-Halevi

“The Jewish brain continues to invent new things like it always did,” said Shmuel Zysman, the founder of ZAG-S&W, who was asked to explain the rousing success of Israeli biomed firms listed on the NASDAQ. “There’s tremendous productivity, extraordinary innovation, technological creativity, leadership and management structures that instituted a global vision from day one,” he said. “These are the ingredients for success that we have noticed among our clients.”

“This hasn’t changed, and we always discover a new dimension,” he said. “We saw this in the hi-tech field, and today it’s biotech. There’s no reason to be surprised. There’s something very bold, innovative, and creative in the Israeli mind, and today Israeli biomed is what is happening when it comes to IPOs. There’s no doubt that we are seeing a wonderful year. The numbers are tremendous and they speak for themselves.”

The law firm of ZAG-S&W serves as the model template for a powerhouse Israeli-American firm, with branches in New York, Boston, Washington, Beijing, Shanghai, and Shenzhen. It also has desks in India and Europe. The firm’s clients worldwide receive legal and commercial service 24 hours a day, seven days a week thanks to its team of Israeli, American, and Chinese attorneys. In the U.S. alone, the firm handles over 15 Israeli companies whose shares are traded on the NASDAQ.

“There are a few reasons at the root of the interest in Israeli companies,” Zysman said. “As an international law firm, our investors are usually foreigners as well as people who have a unique familiarity with the field in which they invest. They know exactly what the risk is, and what the reward is, and they wait for Israeli companies to offer their wares.”

“Compared to other foreign biomed companies, the Israeli companies come with a lower price tag,” he said. “If an Israeli company and an American company offered the same product, the American brand would be much more expensive. That is why some of the speculative investors see Israeli firms as having far more potential because the upside is much bigger. Also, Israeli companies have a good reputation. The investors realize this, and they carefully consider every Israeli company that comes in.”

For years now, Israel has become a center for biomed companies. It has enjoyed the benefits of foreign investors who have been attracted by the potential the country offers. Israel has numerous biomed and biotech hubs nestled in industrial parks in Rehovot, Caesarea, Haifa, and Yokneam. Within the next few years, Be’er Sheva is expected to turn into a technological greenhouse in the wake of the ribbon-cutting of the Bionegev Innovation Cluster.

The Israeli biomed community is gradually gaining a reputation worldwide, and it is expected to become a model for others to emulate, just like hi-tech. The success of Israeli companies in the American biomed market stems from all the changes that took shape in the health field in the United States last year. Nonetheless, most of these changes pose new challenges to Israeli firms, requiring them to adjust themselves accordingly with the latest developments.

This will not be an easy undertaking. That is why there are those who believe that the success we have seen recently is indicative of a bubble. To buttress their argument, they point to the triple- and quadruple-digit returns. Ultimately, however, not all of these IPOs will pan out.

“I’m aware of how some analysts are talking in terms of this being a bubble,” Zysman said. “These companies are capable of making tenfold profits of any other company. That is why there is an element of risk versus reward because there is a certain risk that some of these IPOs will ultimately not lead to the desired result, which is an effective, safe drug or a life-saving medical device.”

About the Author: Ranit Nachum-Halevi is a consultant to real estate companies, and former senior real estate correspondent for The Marker, Haaretz's daily financial supplement. She has been working in Israel's media for more than 15 years. You can reach her at ranit.nh@gmail.com.


If you don't see your comment after publishing it, refresh the page.

Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.

If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.

No Responses to “The Israeli Dash to the NASDAQ”

Comments are closed.

SocialTwist Tell-a-Friend

Current Top Story
IDF soldiers examine fragments from a rocket that landed near Kibbutz El Rom, fired from Syria on July 14, 2014.
Mortar Fire in Golan Heights ‘Due to Syrian War’
Latest Indepth Stories
Mark Twain

Twain grasped amazingly well the pulse of the Jewish people.

Brudner-012414-Hollywood

The entertainment industry appears divided about the conflict between Israel and Hamas.

Grandparents of 4 year old Daniel Tragerman mourn during his funeral at the Hevel Shalom Cemetery in Southern Israel. The boy was murdered by Hamas.

Israelis in Gaza border communities need to get out; who will help them?

Jackie Mason

The contrast between the mentality of Israel and the mentality of Hamas was never so loudly expressed as when the Arab killers became heroes and the Jewish killers became prisoners.

There is a threat today representing a new category of missionary:They call themselves “Hayovel.”

Just as we would never grant legitimacy to ISIS, we should not grant legitimacy to Hamas.

Is Woodstock still leading the world to destruction?

Wye would be seen to have set the groundwork for the creation of a Palestinian state

Blaming Israel for the violence in Gaza, he ends up justifying Hamas’s terrorism.

In the Thirties it was common for anti-Semites to call on Jews to “go to Palestine!”

Obama never hid his contempt for the Israeli government or the majority of Israel’s voters.

“This arbitrary ban is an ugly stain on our democracy, and it also undermines the rule of law.”

We take US “aid” for psychological reasons-if we have an allowance, that means we have a father.

ZIM Piraeus isn’t Israeli-owned or flagged, incidentally, it is Greek operated.

Foolish me, thinking the goals were the destruction of Hamas thereby giving peace a real chance.

The free-spirted lifestyle didn’t hold your interest; the needs of your people did.

More Articles from Ranit Nachum-Halevi
On the beach

Israel’s coastline may be short, but there are still some real estate pearls waiting to be realized, offering cheap alternatives for sea front living. All you have to do is go further from the boundaries of Tel-Aviv and the Dan Block.

Meir Shitrit speaks with the press.

Nave and Golan are advisors helping Meir Sheetrit run for president. As professionals who lead campaigns and shape public opinion, they cite the press as a major factor in this campaign.

Israeli biomedical firms look back on a successful year on Wall Street. Are we bearing witness to “the new tech”?

The romantic skyline of Jerusalem is disappearing. Is Jerusalem on its way to becoming a modern city? Or is it losing its special character?

Government plans to market 12,000 new apartments in Modi’in, where prices haven’t stopped rising in recent years.

It’s a boom: some 100,000 housing units will replace military camps in the high-value center of Israel.

    Latest Poll

    Do you think the FAA ban on US flights to Israel is political?






    View Results

    Loading ... Loading ...

Printed from: http://www.jewishpress.com/indepth/analysis/the-israeli-dash-to-the-nasdaq/2014/05/01/

Scan this QR code to visit this page online: